Treatment of gastroduodenal Crohn's disease

被引:17
|
作者
Mottet, C
Juillerat, P
Gonvers, JJ
Michetti, P
Burnand, B
Vader, JP
Felley, C
Froehlich, F
机构
[1] Univ Lausanne, Med Ctr, Div Gastroenterol & Hepatol, CH-1011 Lausanne, Switzerland
[2] Univ Basel, Gastrointestinal Dept, Basel, Switzerland
[3] Univ Lausanne, Inst Social & Prevent Med, Lausanne, Switzerland
关键词
Crohn's disease; esophagus; stomach; duodenum; stenosis; therapy;
D O I
10.1159/000083871
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Symptomatic gastroduodenal manifestations of Crohn's disease ( CD) are rare, with less than 4% of patients being clinically symptomatic. Gastroduodenal involvement may, however, be found endoscopically in 20% and in up to 40% of cases histologically, most frequently as Helicobacter pylori - negative focal gastritis, usually in patients with concomitant distal ileal disease. In practice, the activity of concomitant distal CD usually determines the indication for therapy, except in the presence of obstructive gastroduodenal symptoms. With the few data available, it seems correct to say that localized gastroduodenal disease should be treated with standard medical therapy used for more distal disease, with the exception of sulfasalazine and mesalanine with pH-dependent release. Presence of symptoms of obstruction needs aggressive therapy. If medical therapy with steroids and immunomodulatory drugs does not alleviate the symptoms, balloon dilation and surgery are the options to consider. Copyright (C) 2005 S. Karger AG, Basel.
引用
收藏
页码:37 / 40
页数:4
相关论文
共 50 条
  • [31] Treatment of Crohn's disease
    Bartoska, Petr
    Paluch, Zoltan
    GAZZETTA MEDICA ITALIANA ARCHIVIO PER LE SCIENZE MEDICHE, 2022, 181 (10) : 769 - 783
  • [32] Ustekinumab for Crohn Disease With Severe Gastroduodenal Involvement
    Fasoulas, Konstantinos
    Stergiou, Evdoxia
    Soufleris, Konstantinos
    INFLAMMATORY BOWEL DISEASES, 2021, 27 (10) : E123 - E123
  • [33] Mucosal proinflammatory cytokine and chemokine expression of gastroduodenal lesions in Crohn's disease
    Moriyama, T
    Matsumoto, T
    Jo, Y
    Yada, S
    Hirahashi, M
    Yao, T
    Iida, M
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 : 85 - 91
  • [34] Increased numbers of macrophages in noninflamed gastroduodenal mucosa of patients with Crohn's disease
    Yao, K
    Iwashita, A
    Yao, T
    Takemura, S
    Furukawa, K
    Matsui, T
    Aoyagi, K
    DIGESTIVE DISEASES AND SCIENCES, 1996, 41 (11) : 2260 - 2267
  • [35] Typical gastroduodenal endoscopic findings in a Crohn's disease patient in remission stage
    Iizuka, Masahiro
    Harada, Taku
    Yamano, Hiro-o
    Etou, Takeshi
    Sagara, Shiho
    WORLD JOURNAL OF GASTROINTESTINAL ENDOSCOPY, 2012, 4 (03): : 96 - 98
  • [36] Symptomatic gastroduodenal Crohn's disease (GCD) requires aggressive immunomodulator therapy
    Selby, L
    De Villiers, WJS
    Annis, K
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (09): : S272 - S273
  • [37] Crohn's disease and its treatment
    Reyt, Vincent
    ACTUALITES PHARMACEUTIQUES, 2019, 58 (583): : 44 - 48
  • [38] Adalimumab for the treatment of Crohn's disease
    Cassinotti, Andrea
    Ardizzone, Sandro
    Porro, Gabriele Bianchi
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (04): : 763 - 777
  • [39] Vedolizumab for the treatment of Crohn's disease
    Argollo, Marjorie
    Fiorino, Gionata
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2018, 14 (03) : 179 - 189
  • [40] Ustekinumab for the treatment of Crohn's disease
    Khanna, Reena
    Feagan, Brian G.
    IMMUNOTHERAPY, 2013, 5 (08) : 803 - 815